The Rutgers Cancer Institute of New Jersey announced it has begun a clinical trial that will examine whether an anti-malaria drug doctors are administering as an off-label use to treat the coronavirus is more effective when taken with an antibiotic. Clinical trials take year to complete. But Rutgers, a nationally recognized comprehensive cancer center, has the in-house expertise to move faster, said Rutgers Cancer Institute Director Steven K. Libutti, who is overseeing the trial. To read the full article.
Recent Posts
- Anonymous Distribution of Naloxone via Vending Machines Raises Uptake by Ex-Prisoners, Rutgers Researchers Find.
- New NJACTS Publication
- Rutgers Researchers Help Redefine Core Microbiome, Opening New Chapter in Precision Health.
- Interested in Accessing Clinical Data?
- Rutgers Health has big plans to spend $47.5M on new ideas at gleaming new Helix tower.
Categories
- Community (2,072)
- Covid (979)
- CTO Events (5)
- News (2,633)
- Pilots (20)